GENETIC TECHNOLOGIES LTD (Form: 6-K, Received: 10/15/2018 17:28:48)

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

dated October 15, 2018

Commission File Number 0-51504

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 15, 2018

	GENETIC TECHNOLOGIES LIMITED


	By:	/s/ Kevin Fischer
		Name:	Kevin Fischer
		Title:	Company Secretary

EXHIBIT INDEX

Exhibit		Description of Exhibit

99.1		ASX Announcement, October 15, 2018

Exhibit 99.1

ASX ANNOUNCEMENT

15 October 2018

Lapse of Employee Share Options

Melbourne, Australia; 15 October 2018 : Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) advises that 14,236,111 unlisted share options granted pursuant to the Company’s employee option plan have lapsed. The details of these lapsed options are:

Unlisted employee option reference	Exercise price		Options lapsed
GTGAD (expiring 24 November 2020)	$	0.020	14,236,111
Total			14,236,111

Accordingly, as at the date of this announcement, as summarised below, there are a total of 53,366,667 outstanding options over shares in the Company.

Unlisted employee options	Exercise price		Options lapsed
GTGAD (expiring 24 November 2020)	$	0.020	5,000,000
GTGAD (expiring 31 March 2021)	$	0.020	5,000,000
GTGAD (expiring 16 February 2022)	$	0.010	10,500,000
Unlisted options pursuant to equity placement facility
GTGAD (expiring 8 August 2021)	$	0.0153	12,500,000
Unlisted options attached to convertible notes
GTGAC (expiring 2 December 2018)	$	0.015	20,366,667
Total			53,366,667

FOR FURTHER INFORMATION PLEASE CONTACT

Dr Paul Kasian		Jason Wong (USA)
Chairman and Interim CEO		Blueprint Life Science Group
Genetic Technologies Limited		+1 (415) 375 3340, Ext. 4
+ 61 3 8412 7000

Genetic Technologies Limited · Website : www.gtglabs.com · Email : info@gtglabs.com ABN 17 009 212 328

Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia
Phone +61 3 8412 7000 · Fax +61 3 8412 7040

About Genetic Technologies Limited

Genetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across Genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGen plus ® , is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

Safe Harbor Statement

Any statements in this press release that relate to the Company’s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. Additional risks associated with Genetic Technologies’ business can be found in its periodic filings with the SEC.